6.81
0.77 (12.75%)
| Previous Close | 6.04 |
| Open | 6.02 |
| Volume | 958,041 |
| Avg. Volume (3M) | 512,254 |
| Market Cap | 64,131,780 |
| Price / Sales | 10.25 |
| Price / Book | 0.770 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Operating Margin (TTM) | -981.18% |
| Diluted EPS (TTM) | -9.42 |
| Total Debt/Equity (MRQ) | 32.52% |
| Current Ratio (MRQ) | 9.41 |
| Operating Cash Flow (TTM) | -62.63 M |
| Levered Free Cash Flow (TTM) | -61.34 M |
| Return on Assets (TTM) | -29.82% |
| Return on Equity (TTM) | -60.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Korro Bio, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 1.13 |
|
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 6.18% |
| % Held by Institutions | 104.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tri Locum Partners Lp | 30 Sep 2025 | 337,764 |
| 72 Investment Holdings, Llc | 30 Sep 2025 | 276,831 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 93.00 (Clear Street, 1,265.64%) | Buy |
| Median | 8.00 (17.47%) | |
| Low | 7.00 (Chardan Capital, 2.79%) | Hold |
| Average | 36.00 (428.63%) | |
| Total | 1 Buy, 2 Hold | |
| Avg. Price @ Call | 17.97 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 13 Nov 2025 | 7.00 (2.79%) | Hold | 6.50 |
| RBC Capital | 13 Nov 2025 | 8.00 (17.47%) | Hold | 6.50 |
| Clear Street | 31 Oct 2025 | 93.00 (1,265.64%) | Buy | 40.91 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2025 | Announcement | Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |